Temasek Holdings Private Ltd Sells 56,944 Shares of BeOne Medicines Ltd. – Sponsored ADR $ONC

Temasek Holdings Private Ltd trimmed its stake in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 6.2% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 862,643 shares of the company’s stock after selling 56,944 shares during the period. BeOne Medicines makes up about 0.8% of Temasek Holdings Private Ltd’s investment portfolio, making the stock its 26th biggest position. Temasek Holdings Private Ltd’s holdings in BeOne Medicines were worth $256,179,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in ONC. Mariner LLC grew its stake in BeOne Medicines by 3.8% in the 4th quarter. Mariner LLC now owns 883 shares of the company’s stock worth $269,000 after acquiring an additional 32 shares in the last quarter. Signaturefd LLC raised its stake in shares of BeOne Medicines by 10.7% during the fourth quarter. Signaturefd LLC now owns 340 shares of the company’s stock valued at $103,000 after acquiring an additional 33 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of BeOne Medicines by 21.8% during the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock valued at $66,000 after acquiring an additional 39 shares in the last quarter. CWM LLC boosted its holdings in shares of BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after purchasing an additional 39 shares during the period. Finally, Benjamin Edwards Inc. boosted its holdings in shares of BeOne Medicines by 8.0% in the fourth quarter. Benjamin Edwards Inc. now owns 690 shares of the company’s stock valued at $210,000 after purchasing an additional 51 shares during the period. 48.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Lai Wang sold 1,068 shares of BeOne Medicines stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $276.74, for a total value of $295,558.32. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Xiaobin Wu sold 1,292 shares of the business’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $276.26, for a total value of $356,927.92. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 233,647 shares of company stock worth $70,335,553 in the last three months. Corporate insiders own 6.19% of the company’s stock.

BeOne Medicines Price Performance

Shares of ONC opened at $318.68 on Wednesday. The company has a 50 day moving average price of $290.28 and a 200-day moving average price of $309.09. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $253.95 and a fifty-two week high of $385.22. The stock has a market capitalization of $34.97 billion, a PE ratio of 71.29 and a beta of 0.49. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The firm had revenue of $1.51 billion for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. Equities analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Morgan Stanley reissued an “overweight” rating and issued a $395.00 price objective on shares of BeOne Medicines in a research note on Thursday, May 7th. Citizens Jmp reaffirmed a “market outperform” rating and set a $396.00 target price on shares of BeOne Medicines in a research report on Wednesday, July 1st. Royal Bank Of Canada upped their target price on BeOne Medicines from $436.00 to $451.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Truist Financial increased their price target on BeOne Medicines from $413.00 to $416.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $390.92.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.